Plasma alkaline phosphatase is elevated in Alzheimer's disease and inversely correlates with cognitive function

International Journal of Molecular Epidemiology and Genetics

Volumn 2, Issue 2, 2011, Pages 114-121

  Kellett, Katherine A B ^a   Williams, Jonathan ^b   Vardy, Emma R L C ^a   Smith, A David ^b   Hooper, Nigel M ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Alkaline phosphatase; Alzheimer's; Cognitive function; Mild cognitive impairment; Plasma

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; APOLIPOPROTEIN E4; CALCIUM; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; MEMANTINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATE;

AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ALZHEIMER DISEASE; ARTICLE; CLINICAL ASSESSMENT; COGNITION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT;

EID: 79958162295     PISSN: None     EISSN: 19481756     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Mount C and Downton C. Alzheimer disease: progress or profit? Nat Med 2006; 12: 780-784.
2. [Burns A and Iliffe S. Alzheimer's disease. BMJ 2009; 338: 467-471.
3. Matthews FE, McKeith I, Bond J and Brayne C. Reaching the population with dementia drugs: what are the challenges? Int J Geriatr Psychiatry 2007; 22: 627-631.
4. Brayne C. The elephant in the room - healthy brains in later life, epidemiology and public health. Nat Rev Neurosci 2007; 8: 233-239.
5. Moss DW. Physicochemical and pathophysiological factors in the release of membranebound alkaline phosphatase from cells. Clin Chim Acta 1997; 257: 133-140.
6. Van Hoof VO and De Broe ME. Interpretation and clinical significance of alkaline phosphatase isoenzyme patterns. Crit Rev Clin Lab Sci 1994; 31: 197-293.
7. Millan JL and Fishman WH. Biology of human alkaline phosphatases with special reference to cancer. Crit Rev Clin Lab Sci 1995; 32: 1-39.
8. Goldstein DJ, Rogers CE and Harris H. Expression of alkaline phosphatase loci in mammalian tissues. Proc Natl Acad Sci U S A 1980; 77: 2857-2860.
9. Fonta C, Negyessy L, Renaud L and Barone P. Areal and subcellular localization of the ubiquitous alkaline phosphatase in the primate cerebral cortex: evidence for a role in neurotransmission. Cereb Cortex 2004; 14: 595-609.
10. Waymire KG, Mahuren JD, Jaje JM, Guilarte TR, Coburn SP and MacGregor GR. Mice lacking tissue non-specific alkaline phosphatase die from seizures due to defective metabolism of vitamin B-6. Nat Genet 1995; 11: 45-51.
11. Narisawa S, Wennberg C and Millan JL. Abnormal vitamin B6 metabolism in alkaline phosphatase knock-out mice causes multiple abnormalities, but not the impaired bone mineralization. J Pathol 2001; 193: 125-133.
12. Langer D, Ikehara Y, Takebayashi H, Hawkes R and Zimmermann H. The ectonucleotidases alkaline phosphatase and nucleoside triphosphate diphosphohydrolase 2 are associated with subsets of progenitor cell populations in the mouse embryonic, postnatal and adult neurogenic zones. Neuroscience 2007; 150: 863-879.
13. Lampl Y, Paniri Y, Eshel Y and Sarova-Pinchas I. Alkaline phosphatase level in CSF in various brain tumors and pulmonary carcinomatous meningitis. J Neurooncol 1990; 9: 35-40.
14. Yamashita M, Sasaki M, Mii K, Tsuzuki M, Takakura K, Yoshinoya S and Ohkubo A. Measurement of serum alkaline phosphatase isozyme I in brain-damaged patients. Neurol Med Chir (Tokyo) 1989; 29: 995-998.
15. Meythaler JM, Hazlewood J, DeVivo MJ and Rosner M. Elevated liver enzymes after nontraumatic intracranial hemorrhages. Arch Phys Med Rehabil 1998; 79: 766-771.
16. Haass C and Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid [beta]-peptide. Nat Rev Mol Cell Biol 2007; 8: 101-112.
17. Cacabelos R, Fernandez-Novoa L, Corzo L, Amado L, Pichel V, Lombardi V and Kubota Y. Phenotypic profiles and functional genomics in Alzheimer's disease and in dementia with a vascular component. Neurol Res 2004; 26: 459-480.
18. Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, Verma S and Goddard R. CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 1986; 149: 698-709.
19. Henderson AR. Enzymes. In: Burtis CA, Ashwood ER, editors. Tietz Fundamentals of Clinical Chemistry. 5th. Philadelphia: W. B. Saunders; 2001. p. 352-389.
20. Endres DB and Rude RK. Mineral and Bone Metabolism. In: Burtis CA, Ashwood ER, editors. Tietz Fundamentals of Clinical Chemistry. 5th. Philadelphia: W.B. Saunders; 2001. p. 795-821.
21. Doumas BT and Biggs HG. Determination of serum albumin. In: Cooper CA, editors. Standard Methods of Clinical Chemistry. New York: Academic Press Inc.; 1972. p. 175.
22. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ and et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43: 1467-1472.
23. Martins CA, Oulhaj A, de Jager CA and Williams JH. APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model. Neurology 2005; 65: 1888-1893.
24. Vardy ER, Rice PJ, Bowie PC, Holmes JD, Grant PJ and Hooper NM. Increased Circulating Insulin- like Growth Factor-1 in Late-onset Alzheimer's Disease. J Alzheimers Dis 2007; 12: 285-290.
25. Lehtimaki T, Pirttila T, Mehta PD, Wisniewski HM, Frey H and Nikkari T. Apolipoprotein E (apoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease. Hum Genet 1995; 95: 39-42.
26. Bertram L, McQueen MB, Mullin K, Blacker D and Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 2007; 39: 17-23.
27. Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL, Hooper C, Rijsdijk F, Tabrizi SJ, Banner S, Shaw CE, Foy C, Poppe M, Archer N, Hamilton G, Powell J, Brown RG, Sham P, Ward M and Lovestone S. Proteomebased plasma biomarkers for Alzheimer's disease. Brain 2006; 129: 3042-3050.
28. Yu HL, Chertkow HM, Bergman H and Schipper HM. Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma. Proteomics 2003; 3: 2240-2248.
29. Maes OC, Kravitz S, Mawal Y, Su H, Liberman A, Mehindate K, Berlin D, Sahlas DJ, Chertkow HM, Bergman H, Melmed C and Schipper HM. Characterization of alpha1-antitrypsin as a heme oxygenase-1 suppressor in Alzheimer plasma. Neurobiol Dis 2006; 24: 89-100.
30. Tham A, Nordberg A, Grissom FE, Carlsson-Skwirut C, Viitanen M and Sara VR. Insulin-like growth factors and insulin-like growth factor binding proteins in cerebrospinal fluid and serum of patients with dementia of the Alzheimer type. J Neural Transm Park Dis Dement Sect 1993; 5: 165-176.
31. Vardy ER, Rice PJ, Bowie PC, Holmes JD, Catto AJ and Hooper NM. Plasma Angiotensinconverting enzyme in Alzheimer's disease. J Alzheimers Dis 2009; 16: 609-618.
32. Matsubara E, Hirai S, Amari M, Shoji M, Yamaguchi H, Okamoto K, Ishiguro K, Harigaya Y and Wakabayashi K. Alpha 1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia. Ann Neurol 1990; 28: 561-567.
33. Hinds TR, Kukull WA, Van Belle G, Schellenberg GD, Villacres EC and Larson EB. Relationship between serum alpha 1-antichymotrypsin and Alzheimer's disease. Neurobiol Aging 1994; 15: 21-27.
34. Lieberman J, Schleissner L, Tachiki KH and Kling AS. Serum alpha 1-antichymotrypsin level as a marker for Alzheimer-type dementia. Neurobiol Aging 1995; 16: 747-753.
35. Merched A, Xia Y, Visvikis S, Serot JM and Siest G. Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol Aging 2000; 21:27-30.
36. Liu HC, Hu CJ, Chang JG, Sung SM, Lee LS, Yuan RY and Leu SJ. Proteomic identification of lower apolipoprotein A-I in Alzheimer's disease. Dement Geriatr Cogn Disord 2006; 21: 155-161.
37. Aluise CD, Sowell RA and Butterfield DA. Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease. Biochim Biophys Acta 2008; 1782: 549-558.
38. Diaz-Hernandez M, Gomez-Ramos A, Rubio A, Gomez-Villafuertes R, Naranjo JR, Miras-Portugal MT and Avila J. Tissue-nonspecific alkaline phosphatase promotes the neurotoxicity effect of extracellular tau. J Biol Chem 2010; 285: 32539-32548.